Skip to content
Clinical Trials – home

Universitaetsklinikum Schleswig-Holstein AöR

Verified siteinfo

Germany Arnold-Heller-Strasse 3, Brunswik, 24105 Kiel, Germany

  • 164 trials recruiting
  • Colitis ulcerative · Crohn's disease · Dermatitis atopic
  • Adults and children

About Specializations

Universitaetsklinikum Schleswig-Holstein AöR in Kiel, Germany specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Dermatitis atopic, Psoriasis, and other specialisations. This site conducts important research.

Main research areas of the site

Dermatology and Immune-Mediated Skin Disease

The Dermatologie department at Universitaetsklinikum Schleswig-Holstein AöR in Kiel is active in research on skin and connective tissue diseases and broader immune system diseases. Much of the work focuses on common chronic inflammatory conditions such as atopic dermatitis, psoriasis, hidradenitis suppurativa, bullous pemphigoid, and prurigo nodularis, with trials aimed at testing new therapies and improving long-term disease control.

  • Atopic dermatitis, psoriasis, and hidradenitis suppurativa research centered on better symptom control and durable treatment responses
  • Bullous pemphigoid studies evaluating newer immune-targeted treatment options for this rare blistering disorder
  • Prurigo nodularis and related itch-driven skin conditions focused on relieving chronic discomfort and improving quality of life
  • Vitiligo and cutaneous lupus erythematosus trials exploring immune-based approaches for inflammatory skin disease

Overall, the site supports a strong dermatology portfolio that combines inflammation, autoimmunity, and itch-related skin disorders in studies designed to refine treatment effectiveness and long-term safety.

Gastroenterology and Inflammatory Bowel Disease

Another major research focus is digestive system disease, especially Crohn’s disease and ulcerative colitis. These trials examine whether newer targeted and immune-modulating treatments can improve remission, bowel healing, and day-to-day disease control for people living with chronic inflammatory bowel disease.

  • Crohn’s disease studies aimed at reducing inflammation and achieving deeper intestinal healing
  • Ulcerative colitis trials assessing better control of active disease and sustained remission
  • Fistulizing perianal Crohn’s disease research addressing one of the more complex forms of inflammatory bowel disease
  • Transmural healing and disease-modifying approaches that look beyond symptom relief alone

At Universitaetsklinikum Schleswig-Holstein AöR, this area reflects a clear interest in improving both the effectiveness and the long-term impact of treatment for chronic gastrointestinal inflammation.

Hematology, Lymphoma, and Stem Cell Transplantation

The site has a substantial portfolio in hemic and lymphatic diseases, with many studies in acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple forms of lymphoma. Research also extends to stem cell transplantation and graft-versus-host disease, reflecting a strong interest in improving outcomes for patients with blood cancers and transplant-related complications.

  • Acute myeloid leukemia and acute lymphoblastic leukemia trials exploring more effective treatment strategies for newly diagnosed and relapsed disease
  • Chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma studies focused on better disease control and deeper remission
  • Multiple myeloma and other B-cell malignancies research evaluating newer immune and targeted therapies
  • Allogeneic hematopoietic stem cell transplantation and graft-versus-host disease studies aimed at improving transplant safety and recovery

This is one of the most active research areas at the site, combining oncology, immunology, and cell therapy to advance care for complex hematologic diseases.

Solid Tumors and Oncology

Clinical research in neoplasms and broader oncology covers a wide range of cancers, including breast cancer, melanoma, lung cancer, ovarian cancer, head and neck cancer, endometrial cancer, and urothelial carcinoma. These studies are generally designed to test new treatment combinations, improve survival, or reduce the risk of recurrence after standard therapy.

  • Breast cancer research spanning early-stage, locally advanced, and metastatic disease
  • Melanoma and cutaneous squamous cell carcinoma trials focused on advanced skin cancers and recurrence prevention
  • Lung cancer, pleural mesothelioma, and head and neck cancer studies evaluating treatment effectiveness in difficult-to-treat tumors
  • Ovarian cancer, endometrial cancer, and urothelial carcinoma research aimed at improving outcomes in advanced disease

The oncology program at Universitaetsklinikum Schleswig-Holstein AöR shows broad activity across both common and rare cancers, with a strong emphasis on better disease control and longer survival.

Cardiovascular, Neurological, and Autoimmune Research

The trial portfolio also includes important work in cardiovascular diseases, nervous system diseases, and immune-mediated disorders. Research topics include heart failure, stroke, hypertension, Alzheimer’s disease, epilepsy, multiple sclerosis, and systemic autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis.

  • Heart failure, aortic stenosis, and broader cardiovascular disease studies focused on improving outcomes and reducing complications
  • Acute ischemic stroke and transient ischemic attack research aimed at preventing disability and recurrent events
  • Epilepsy, multiple sclerosis, and Alzheimer’s disease trials exploring better symptom management and disease modification
  • Autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis assessing new immune-targeted treatments

These studies highlight the site’s wider research reach beyond dermatology, with a focus on chronic diseases where better control, safety, and quality of life remain central goals.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Arnold-Heller-Strasse 3, Brunswik24105 KielGermany
Recruiting now
164 trials
Conditions studied
222
Partner status
Verified site

More sites in KielGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

388 clinical trials

Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Eczema nummular

Recruiting

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:XMAB942
  • Sponsor:Xencor Inc.

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.